Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study to investigate the safety and tolerability of GK Activator (2) in patients with type 2 diabetes mellitus not adequately controlled with glimepiride as a standard prescribed therapy.

Trial Profile

An open label study to investigate the safety and tolerability of GK Activator (2) in patients with type 2 diabetes mellitus not adequately controlled with glimepiride as a standard prescribed therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Glimepiride; Piragliatin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Actual initiation date (Aug 2006) added as reported by Roche.
    • 08 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top